Funding Decisions

AstraZeneca Impact Challenge Grant - Cardiovascular/Diabetes 2017

Competition Deadline Date: March 31, 2017

In 2013 the Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research (HSRLCE) and the Banting & Best Diabetes Center (BBDC) in conjunction with the Vice-Dean, Research and International Relations, Faculty of Medicine announced that they would be funding research initiatives focusing on Diabetes and Heart Disease. In 2014 we partnered with AstraZeneca to introduce the AstraZeneca Impact Challenge Grant. The annual $250,000 award is intended to address a significant health issue: the prevalence of cardiovascular disease in patients with diabetes.

2017 Recipient

RecipientTitle of ResearchAmount

Principal Applicant: Dr. David Cherney
Co-Applicants:
Dr. Daniel Drucker
Dr. John Floras
Dr. Mansoor Husain
Dr. Susanna Mak
Dr. John Parker
Dr. Bruce Perkins
Dr. Jacob Udell

iNcretin And TReatment with Inhibition of sodiUm-glucose cotRansportEr-2 combinaTion In Congestive Heart Failure Preserved Ejection Fraction Trial (“NATRIURETIC-pEF”)$249,863

 

About This Project

Patients with type 2 diabetes (T2D) are at risk for accumulating fluid in the heart and lungs – a condition called “heart failure”. Fortunately, a new class of medication that is used to control blood sugar levels in patients with T2D – called sodium glucose co-transport-2 inhibitors (SGLT2i) – was recently shown to reduce the risk of dying or developing heart failure and decrease the risk of progressive diabetes-related kidney damage. Other diabetes medications that are used to control blood sugar levels called “incretins” (e.g. “glucagon-like peptide-1 receptor agonist” or GLP1RA) also cause sodium loss in the urine and reduce the risk of death and diabetic kidney damage. Both medications have a number of important kidney and heart effects, including reductions in blood pressure and weight. In addition, both medications cause salt and water loss in the urine. This may be beneficial in heart failure patients, who accumulate salt and fluid around their lungs and also to develop swelling of their legs. Despite these effects, it is not known why patients with heart failure benefit from SGLT2i or GLP1RA, nor is it known if the combination of SGLT2i with GLP1-RA leads to further improvements in the heart or kidney that are more powerful than either drug alone. Our aim is to measure changes in kidney and heart function, and levels of salt and water in the body to understand how combined SGLT2i-GLP1RA reduce heart failure risk in T2D.